

Publications 2017

Equipe 1 Tolérance Immunitaire dépendante des lymphocytes T (J. Van Meerwijk)

1. Darrigues J, van Meerwijk JPM, Romagnoli P. *Age-Dependent Changes in Regulatory T Lymphocyte Development and Function: A Mini-Review.* **Gerontology.** 2017 Jul 14. doi: 10.1159/000478044. [Epub ahead of print]

2. Apert C, Romagnoli P, van Meerwijk JPM. *IL-2 and IL-15 dependent thymic development of Foxp3-expressing regulatory T lymphocytes.* **Protein Cell.** 2017 May 24. doi: 10.1007/s13238-017-0425-3. [Epub ahead of print] Review.

3. Vuddamalay Y, van Meerwijk JP. *CD28⁻ and CD28^{low}CD8⁺ Regulatory T Cells: Of Mice and Men.* **Front Immunol.** 2017 Jan 23;8:31. doi: 10.3389/fimmu.2017.00031. eCollection 2017. Review.

Equipe 2 Dynamique moléculaire des interactions lymphocytaires (S. Valitutti)

1. Espinosa E, Valitutti S. *New roles and controls of mast cells* **Curr Opin Immunol.** 2017 Nov 13;50:39-47. doi: 10.1016/j.coi.2017.10.012. [Epub ahead of print] Review.

2. Joulia R, Mailhol C, Valitutti S, Didier A, Espinosa E. *Direct monitoring of basophil degranulation by using avidin-based probes.* **J Allergy Clin Immunol.** 2017 Oct;140(4):1159-1162.e6. doi: 10.1016/j.jaci.2017.03.030. Epub 2017 Apr 20. No abstract available.

3. Valitutti S, Joulia R, Espinosa E. *The Mast Cell Antibody-Dependent Degranulatory Synapse.* **Methods Mol Biol.** 2017;1584:487-495. doi: 10.1007/978-1-4939-6881-7_30.

4. Sarkar K, Han SS, Wen KK, Ochs HD, Dupré L, Seidman MM, Vyas YM. *R-loops cause genomic instability in Wiskott-Aldrich syndrome T_h helper lymphocytes.* **J Allergy Clin Immunol.** 2017 Dec 14. pii: S0091-6749(17)31899-7. doi: 10.1016/j.jaci.2017.11.023. [Epub ahead of print]

5. Pfajfer L, Seidel MG, Houmadi R, Rey-Barroso J, Hirschmugl T, Salzer E, Antón IM, Urban C, Schwinger W, Boztug K, Dupré L. *WIP deficiency severely affects human lymphocyte architecture during migration and synapse assembly.* **Blood.** 2017 Oct 26;130(17):1949-1953. doi: 10.1182/blood-2017-04-777383. Epub 2017 Sep 13. No abstract available.

6. Cotta-de-Almeida V, Dupré L, Savino W. *Editorial: T-Cell Migration in Health and Disease.* **Front Immunol.** 2017 Feb 13;8:132. doi: 10.3389/fimmu.2017.00132. eCollection 2017. No abstract available.

Equipe 3 Différences liées au sexe dans l'immunité : mécanismes et physiopathologie (JC. Guéry)

1. Rosa N, Triffaux E, Robert V, Mars M, Klein M, Bouchaud G, Canivet A, Magnan A, Guéry JC, Pelletier L, Savignac M. *The β and $\alpha 2\delta$ auxiliary subunits of voltage-gated calcium channel 1 (Ca_v1) are required for T_H2 lymphocyte function and acute allergic airway*

inflammation **J Allergy Clin Immunol.** 2017 Nov 10. pii: S0091-6749(17)31740-2. doi: 10.1016/j.jaci.2017.09.045. [Epub ahead of print]

2. Laffont S, Blanquart E, Guéry JC. *Sex Differences in Asthma: A Key Role of Androgen-Signaling in Group 2 Innate Lymphoid Cells* **Front Immunol.** 2017 Aug 31;8:1069. doi: 10.3389/fimmu.2017.01069. eCollection 2017. Review.

3. Laffont S, Blanquart E, Savignac M, Cénac C, Laverny G, Metzger D, Girard JP, Belz GT, Pelletier L, Seillet C, Guéry JC. *Androgen signaling negatively controls group 2 innate lymphoid cells.* **J Exp Med.** 2017 Jun 5;214(6):1581-1592. doi: 10.1084/jem.20161807. Epub 2017 May 8. IF 11.991

4. Laffont S, Seillet C, Guéry JC. *Estrogen Receptor-Dependent Regulation of Dendritic Cell Development and Function.* **Front Immunol.** 2017 Feb 10;8:108. doi: 10.3389/fimmu.2017.00108. eCollection 2017. Review.

5. Basso L, Garnier L, Bessac A, Boué J, Blanpied C, Cenac N, Laffont S, Dietrich G. *T-lymphocyte-derived enkephalins reduce Th1/Th17 colitis and associated pain in mice.* **J Gastroenterol.** 2017 Apr 19. doi: 10.1007/s00535-017-1341-2. [Epub ahead of print]

Equipe 4 Cellules présentatrices de l'Antigène et Réponses T CD4 (S. Guerder/N. Fazilleau)

1. Asrir A, Aloulou M, Gador M, Pérals C, Fazilleau N. *Interconnected subsets of memory follicular helper T cells have different effector functions.* **Nat Commun.** 2017 Oct 10;8(1):847. doi: 10.1038/s41467-017-00843-7. IF

2. Sacquin A, Gador M, Fazilleau N. *The strength of BCR signaling shapes terminal development of follicular helper T cells in mice.* **Eur J Immunol.** 2017 Aug;47(8):1295-1304. doi: 10.1002/eji.201746952. Epub 2017 Jul 3.

3. Serre L, Girard M, Ramadan A, Menut P, Rouquié N, Lucca LE, Mahiddine K, Leobon B, Mars LT, Guerder S. *Thymic-Specific Serine Protease Limits Central Tolerance and Exacerbates Experimental Autoimmune Encephalomyelitis.* **J Immunol.** 2017 Dec 1;199(11):3748-3756. doi: 10.4049/jimmunol.1700667. Epub 2017 Oct 23.

Equipe 5 Maladies inflammatoires du système nerveux : mécanismes et traitements (R. Liblau / A. Saoudi)

1. Yshii LM, Hohlfeld R, Liblau RS. *Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.* **Nat Rev Neurol.** 2017 Dec;13(12):755-763. doi: 10.1038/nrneurol.2017.144. Epub 2017 Nov 6. Review.

2. Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis. *Cell-based therapeutic strategies for multiple sclerosis.* **Brain.** 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.

3. Dywicki J, Noyan F, Misslitz AC, Hapke M, Galla M, Schlue J, Liblau RS, Taubert R, Manns MP, Jaeckel E, Hardtke-Wolenski M. *Hepatic T Cell Tolerance Induction in An Inflammatory Environment*. **Dig Dis**. 2017 Oct 12. doi: 10.1159/000481341. [Epub ahead of print]
4. Barateau L, Liblau R, Peyron C, Dauvilliers Y. *Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment*. **CNS Drugs**. 2017 Oct;31(10):821-834. doi: 10.1007/s40263-017-0464-6.
5. Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH; 2016 ECTRIMS Focused Workshop Group. *Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop*. **Mult Scler**. 2017 Jan 6;1352458516686847. doi: 10.1177/1352458516686847. [Epub ahead of print]
6. Meyer C, Martin-Blondel G, Liblau RS. *Endothelial cells and lymphatics at the interface between the immune and central nervous systems: implications for multiple sclerosis* **Curr Opin Neurol**. 2017 Jun;30(3):222-230. doi: 10.1097/WCO.0000000000000454.
7. Menezes SM, Leal FE, Dierckx T, Khouri R, Decanine D, Silva-Santos G, Schnitman SV, Kruschewsky R, López G, Alvarez C, Talledo M, Gotuzzo E, Nixon DF, Vercauteren J, Brassat D, Liblau R, Vandamme AM, Galvão-Castro B, Van Weyenbergh J. *A Fas^{hi} Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation*. **Front Immunol**. 2017 Feb 14;8:97. doi: 10.3389/fimmu.2017.00097. eCollection 2017.
8. Lecendreux M, Churlaud G, Pitoiset F, Regnault A, Tran TA, Liblau R, Klatzmann D, Rosenzweig M. *Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells*. **PLoS One**. 2017 Jan 20;12(1):e0169836. doi: 10.1371/journal.pone.0169836. eCollection 2017.
9. Fissolo N, Pignolet B, Brassat D, Comabella M. *Reply*. **Ann Neurol**. 2017 Oct;82(4):647-648. doi: 10.1002/ana.25039. Epub 2017 Oct 4.
10. Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best Escalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network. *Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy*. **Ann Neurol**. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.
11. Averseng-Peureaux D, Mizzi M, Colineaux H, Mahieu L, Pera MC, Brassat D, Chaix Y, Berard E, Deiva K, Cheuret E; on behalf of Kidbiosep study group. *Paediatric optic neuritis: factors leading to unfavourable outcome and relapses*. **Br J Ophthalmol**. 2017 Sep 13. pii: bjophthalmol-2016-309978. doi: 10.1136/bjophthalmol-2016-309978. [Epub ahead of print]

12. Secher T, Kassem S, Benamar M, Bernard I, Boury M, Barreau F, Oswald E, Saoudi A. *Oral Administration of the Probiotic Strain Escherichia coli Nissle 1917 Reduces Susceptibility to Neuroinflammation and Repairs Experimental Autoimmune Encephalomyelitis-Induced Intestinal Barrier Dysfunction*. **Front Immunol**. 2017 Sep 14;8:1096. doi: 10.3389/fimmu.2017.01096. eCollection 2017.
13. Garreau A, Blaize G, Argenty J, Rouquié N, Tourdès A, Wood SA, Saoudi A, Lesourne R. *Grb2-Mediated Recruitment of USP9X to LAT Enhances Themis Stability following Thymic Selection*. **J Immunol**. 2017 Oct 15;199(8):2758-2766. doi: 10.4049/jimmunol.1700566. Epub 2017 Sep 6.
14. Duguet F, Locard-Paulet M, Marcellin M, Chaoui K, Bernard I, Andreoletti O, Lesourne R, Burllet-Schiltz O, Gonzalez de Peredo A, Saoudi A. *Proteomic Analysis of Regulatory T Cells Reveals the Importance of Themis1 in the Control of Their Suppressive Function*. **Mol Cell Proteomics**. 2017 Aug;16(8):1416-1432. doi: 10.1074/mcp.M116.062745. Epub 2017 Apr 3.
15. Guerreiro-Cacais AO, Norin U, Gyllenberg A, Berglund R, Beyeen AD; Rheumatoid Arthritis Consortium International (RACI), Petit-Teixeira E, Cornélis F, Saoudi A, Fournié GJ, Holmdahl R, Alfredsson L, Klareskog L, Jagodic M, Olsson T, Kockum I, Padyukov L. *VAV1 regulates experimental autoimmune arthritis and is associated with anti-CCP negative rheumatoid arthritis*. **Genes Immun**. 2017 Jan;18(1):48-56. doi: 10.1038/gene.2016.49. Epub 2017 Jan 5.
16. Ni Choileain S, Hay J, Thomas J, Williams A, Vermeren MM, Benezech C, Gomez-Salazar M, Hugues OR, Vermeren S, Howie SEM, Dransfield I, Astier AL. *TCR-stimulated changes in cell surface CD46 expression generate type 1 regulatory T cells*. **Sci Signal**. 2017 Oct 24;10(502). pii: eaah6163. doi: 10.1126/scisignal.aah6163.
17. Killick J, Morisse G, Sieger D, Astier AL. *Complement as a regulator of adaptive immunity*. **Semin Immunopathol**. 2017 Aug 25. doi: 10.1007/s00281-017-0644-y. [Epub ahead of print] Review.
18. Mansuy JM, Mengelle C, Pasquier C, Chapuy-Regaud S, Delobel P, Martin-Blondel G, Izopet J. *Zika Virus Infection and Prolonged Viremia in Whole-Blood Specimens*. **Emerg Infect Dis**. 2017 May;23(5):863-865. doi: 10.3201/eid2305.161631. Epub 2017 May 15.
19. Palich R, Martin-Blondel G, Cuzin L, Le Talec JY, Boyer P, Massip P, Delobel P. *Experiences of HIV postexposure prophylaxis (PEP) among highly exposed men who have sex with men (MSM)*. **Sex Transm Infect**. 2017 Nov;93(7):493-498. doi: 10.1136/sextrans-2016-052901. Epub 2017 Jul 24.
20. Fournier A, Martin-Blondel G, Lechapt-Zalcman E, Dina J, Kazemi A, Verdon R, Mortier E, de La Blanchardière A. *Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review*.

Front Immunol. 2017 May 23;8:577. doi: 10.3389/fimmu.2017.00577. eCollection 2017. Review.

21. Guery R, Henry B, Martin-Blondel G, Rouzaud C, Cordoliani F, Harms G, Gangneux JP, Foulet F, Bourrat E, Baccard M, Morizot G, Consigny PH, Berry A, Blum J, Lortholary O, Buffet P; French Cutaneous Leishmaniasis Study group & the LeishMan network. *Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.* **PLoS Negl Trop Dis.** 2017 Nov 20;11(11):e0006094. doi: 10.1371/journal.pntd.0006094. eCollection 2017 Nov.

22. Dutertre M, Cuzin L, Demonchy E, Puglièse P, Joly V, Valantin MA, Cotte L, Huleux T, Delobel P, Martin-Blondel G; Dat'AIDS Study Group. *Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization.* **J Acquir Immune Defic Syndr.** 2017 Sep 1;76(1):e23-e26. doi: 10.1097/QAI.0000000000001397.

23. Pericart S, Martin-Blondel G, Franchet C, Hitzel A and Brousset P. *18F Fluorodeoxyglucose positron emission tomography computed tomography detection threshold in follicular lymphoma.* **Medicine** (Baltimore), 96, 47, e8705, 2017

24. Kinoshita PF, Yshii LM, Orellana AMM, Paixão AG, Vasconcelos AR, Lima LS, Kawamoto EM, Scavone C. *Alpha 2 Na⁺,K⁺-ATPase silencing induces loss of inflammatory response and ouabain protection in glial cells.* **Sci Rep.** 2017 Jul 7;7(1):4894. doi: 10.1038/s41598-017-05075-9.

Equipe 6 Infections virales : persistance, réponse de l'hôte et physiopathologie (J. Izopet)

1. Abravanel F, Goutagny N, Perret C, Lhomme S, Vischi F, Aversenq A, Chapel A, Dehainault N, Piga N, Dupret-Carruel J, **Izopet J.** *Evaluation of two VIDAS® prototypes for detecting anti-HEV IgG.* **J Clin Virol** 2017;89:46-50.

2. Abravanel F, Lhomme S, El Costa H, Schvartz B, Peron JM, Kamar N, Izopet J. *Rabbit Hepatitis E Virus Infections in Humans, France.* **Emerg Infect Dis** 2017;23:1191-1193. (IF 8,2)

3. Abravanel F, Lhomme S, Fougere M, Saune K, Alvarez M, Peron JM, Delobel P, Izopet J. *HEV infection in French HIV-infected patients.* **J Infect** 2017;74:310-313.

4. Assoumou L, Charpentier C, Recordon-Pinson P, Grude M, Pallier C, Morand-Joubert L, Fafi-Kremer S, Krivine A, Montes B, Ferre V, Bouvier-Alias M, Plantier JC, Izopet J, Trabaud MA, Yerly S, Dufayard J, Alloui C, Courdavault L, Le Guillou-Guillemette H, Maillard A, Amiel C, Vabret A, Roussel C, Vallet S, Guinard J, Mirand A, Beby-Defaux A, Barin F, Allardet-Servent A, Ait-Namane R, Wirden M, Delaugerre C, Calvez V, Chaix ML, Descamps D, Reigadas S and Group AA-RS. *Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.* **J Antimicrob Chemother** 2017;72:1769-1773.

5. Barrague H, Condat B, Petitdidier N, Champagne E, Renou C, Izopet J, Abravanel F. *Chronic hepatitis E virus infection in a cirrhotic patient: A case report*. **Medicine (Baltimore)** 2017;96:e7915.
6. Belliere J, Abravanel F, Nogier MB, Martinez S, Cintas P, Lhomme S, Lavayssiere L, Cointault O, Faguer S, Izopet J, Kamar N. *Transfusion-acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient*. **Transpl Infect Dis** 2017;19:
7. Braun P, Delgado R, Drago M, Fanti D, Fleury H, Gismondo MR, Hofmann J, Izopet J, Kuhn S, Lombardi A, Marcos MA, Saune K, O'Shea S, Perez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes DW. *European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay*. **J Clin Microbiol** 2017;55:1186-1192.
8. Braun P, Delgado R, Drago M, Fanti D, Fleury H, Hofmann J, Izopet J, Kuhn S, Lombardi A, Mancon A, Marcos MA, Mileto D, Saune K, O'Shea S, Perez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes DW. *A European Multicentre Study on the comparison of HIV-1 viral loads between VERIS HIV-1 Assay and Roche COBAS® TAQMAN® HIV-1 test, Abbott RealTime HIV-1 Assay, and Siemens versant HIV-1 Assay*. **J Clin Virol** 2017;92:75-82.
9. Braun P, Delgado R, Drago M, Fanti D, Fleury H, Hofmann J, **Izopet J**, Kalus U, Lombardi A, Marcos MA, Mileto D, Saune K, O'Shea S, Perez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A and Rhodes DW. *European Multicenter Study on Analytical Performance of Veris HIV-1 Assay*. **J Clin Microbiol** 2017;55:2055-2063.
10. Carre M, Thiebaut-Bertrand A, Larrat S, Leroy V, Pouzol P, Sturm N, Lhomme S, Cahn JY, Garban F, Morand P. *Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation*. **Bone Marrow Transplant** 2017;52:643-645.
11. Chapuy-Regaud S, Dubois M, Plisson-Chastang C, Bonnefois T, Lhomme S, Bertrand-Michel J, You B, Simoneau S, Gleizes PE, Flan B, **Abravanel F**, **Izopet J**. *Characterization of the lipid envelope of exosome encapsulated HEV particles protected from the immune response*. **Biochimie** 2017;141:70-79.
12. Dalton HR, van Eijk JJJ, Cintas P, Madden RG, Jones C, Webb GW, Norton B, Pique J, Lutgens S, Devooght-Johnson N, Woolson K, Baker J, Saunders M, Househam L, Griffiths J, Abravanel F, Izopet J, Kamar N, van Alfen N, van Engelen BGM, Hunter JG, van der Eijk AA, Bendall RP, McLean BN, Jacobs BC. *Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study*. **J Hepatol** 2017;67:925-932.
13. Dam N, Hocine HR, Palacios I, DelaRosa O, Menta R, Charron D, Bensussan A, El Costa H, Jabrane-Ferrat N, Dalemans W, Lombardo E, Al-Daccak R. *Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair*. **Front Immunol** 2017;8:1413.
14. Dharancy S, Coilly A, Fougerou-Leurent C, Duvoux C, Kamar N, Leroy V, Tran A, Houssel-Debry P, Canva V, Moreno C, Conti F, Dumortier J, Di Martino V, Radenne S, De Ledinghen V, D'Alteroche L, Silvain C, Besch C, Perre P, Botta-Fridlund D, Francoz C, Habersetzer F, Montialoux H, Abergel A, Debette-Gratien M, Rohel A, Rossignol E, Samuel

D, Duclos-Vallee JC, Pageaux GP and group ACCs. *Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study.* **Am J Transplant** 2017;17:2869-2878.

15. Donnelly MC, Imlach SN, Abravanel F, Ramalingam S, Johannessen I, Petrik J, Fraser AR, Campbell JD, Bramley P, Dalton HR, Hayes PC, Kamar N, Simpson KJ. *Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.* **Gastroenterology** 2017;152:300-301.

16. Dutertre M, Cuzin L, Demonchy E, Pugliese P, Joly V, Valantin MA, Cotte L, Huleux T, Delobel P, Martin-Blondel G and Dat ASG. *Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization.* **J Acquir Immune Defic Syndr** 2017;76:e23-e26.

17. Gantner P, Melard A, Damond F, Delaugerre C, Dina J, Gueudin M, Maillard A, Saune K, Rodallec A, Tuillon E, Plantier JC, Rouzioux C, Avettand-Fenoel V and Group A-AQW. *Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies.* **J Med Virol** 2017;89:2047-2050.

18. Gatault P, Kamar N, Buchler M, Colosio C, Bertrand D, Durrbach A, Albano L, Rivalan J, Le Meur Y, Essig M, Bouvier N, Legendre C, Moulin B, Heng AE, Weestel PF, Sayegh J, Charpentier B, Rostaing L, Thervet E, Lebranchu Y. *Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.* **Am J Transplant** 2017;17:1370-1379.

19. Gaudre N, Cougoul P, Bartolucci P, Dorr G, Bura-Riviere A, Kamar N, Del Bello A. *Improved Fetal Hemoglobin With mTOR Inhibitor-Based Immunosuppression in a Kidney Transplant Recipient With Sickle Cell Disease.* **Am J Transplant** 2017;17:2212-2214.

20. Grinyo JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N. *Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.* **Am J Kidney Dis** 2017;69:587-594.

21. Hocine HR, El-Costa H, Dam N, Giustiniani J, Palacios I, Loiseau P, Benssusan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R. *Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.* **Sci Rep** 2017;7:41125.

22. Joguet G, Mansuy JM, Matusali G, Hamdi S, Walschaerts M, Pavili L, Guyomard S, Prisant N, Lamarre P, Dejucq-Rainsford N, Pasquier C, Bujan L. *Effect of acute Zika virus infection on sperm and virus clearance in body fluids: a prospective observational study.* **Lancet Infect Dis** 2017;17:1200-1208. (IF 19,9)

23. Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, Dalton HR. *Hepatitis E virus infection.* **Nat Rev Dis Primers** 2017;3:17086.

24. Kamar N, Wang W, Dalton HR, Pan Q. *Direct-acting antiviral therapy for hepatitis E virus?* **Lancet Gastroenterol Hepatol** 2017;2:154-155.

25. Kormann R, Francois H, Moles T, Dantal J, Kamar N, Moreau K, Bachelet T, Heng AE, Garstka A, Colosio C, Ducloux D, Sayegh J, Savenkoff B, Viglietti D, Sberro R, Rondeau E, Peltier J. *Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature*. **PLoS One** 2017;12:e0179406.
26. Kramer BK, Albano L, Banas B, Charpentier B, Backman L, Tedesco-Silva H, Jr., Lehner F, Mondragon-Ramirez GA, Glyda M, Cassuto-Viguier E, Viklicky O, Mourad G, Rigotti P, Schleibner S, Kamar N. *Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials*. **Transplant Proc** 2017;49:2040-2049.
27. Larcher M, Delas A, Delmas C, Cointault O, Dambrin C, Del Bello A, Kamar N. *Unusual Pathology in a Kidney from a Heart-Transplant Patient*. **Case Rep Transplant** 2017;2017:1084718.
28. Le Guillou-Guillemette H, Pivert A, Bouthry E, Henquell C, Petsaris O, Ducancelle A, Veillon P, Vallet S, Alain S, Thibault V, Abravanel F, Rosenberg AA, Andre-Garnier E, Bour JB, Baazia Y, Trimoulet P, Andre P, Gaudy-Graffin C, Bettinger D, Larrat S, Signori-Schmuck A, Saoudin H, Pozzetto B, Lagathu G, Minjolle-Cha S, Stoll-Keller F, Pawlotsky JM, Izopet J, Payan C, Lunel-Fabiani F, Lemaire C. *Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma*. **PLoS One** 2017;12:e0174651.
29. Lelouvier B, Servant F, Delobel P, Courtney M, Elbaz M, Amar J. *Identification by highly sensitive 16S metagenomic sequencing of an unusual case of polymicrobial bacteremia*. **J Infect** 2017;75:278-280.
30. Lhomme S, Bardiaux L, Abravanel F, Gallian P, Kamar N, Izopet J. *Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France*. **Emerg Infect Dis** 2017;23:353-356. (IF 8,2)
31. Mansuy JM, Mengelle C, Pasquier C, Chapuy-Regaud S, Delobel P, Martin-Blondel G, Izopet J. *Zika Virus Infection and Prolonged Viremia in Whole-Blood Specimens*. **Emerg Infect Dis** 2017;23:863-865. (IF 8,2)
32. Metsu D, Seraissol P, Delobel P, Cinq-Frais C, Cuzin L, Izopet J, Chatelut E, Gandia P. *Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?* **Fundam Clin Pharmacol** 2017;31:245-253.
33. Metsu D, Toutain PL, Chatelut E, Delobel P, Gandia P. *Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?* **J Antimicrob Chemother** 2017;72:2407-2409.
34. Milongo D, Kamar N, Del Bello A, Guilbeau-Frugier C, Sallusto F, Esposito L, Dorr G, Blancher A, Congy-Jolivet N. *Allelic and Epitopic Characterization of Intra-Kidney Allograft Anti-HLA Antibodies at Allograft Nephrectomy*. **Am J Transplant** 2017;17:420-431.
35. Montpellier C, Wychowski C, Sayed IM, Meunier JC, Saliou JM, Ankavay M, Bull A, Pillez A, Abravanel F, Helle F, Brochot E, Drobecq H, Farhat R, Aliouat-Denis CM, Haddad

JG, Izopet J, Meuleman P, Goffard A, Dubuisson J, Cocquerel L. *Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein*. **Gastroenterology** 2018;154:211-223 e8.

36. Moulin M, Alguacil J, Gu S, Mehtougui A, Adams EJ, Peyrottes S, Champagne E. *Vgamma9Vdelta2 T cell activation by strongly agonistic nucleotidic phosphoantigens*. **Cell Mol Life Sci** 2017;74:4353-4367.

37. Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Kramer BK, Metselaar HJ, Nevens F, Pirenne J, Rodriguez-Peralvarez ML, Samuel D, Schneeberger S, Seron D, Trunecka P, Tisone G, van Gelder T. *Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group*. **Transplantation** 2017;101:S1-S56.

38. Palich R, Martin-Blondel G, Cuzin L, Le Talec JY, Boyer P, Massip P, Delobel P. *Experiences of HIV postexposure prophylaxis (PEP) among highly exposed men who have sex with men (MSM)*. **Sex Transm Infect** 2017;93:493-498.

39. Pasquier C, Joguet G, Mengelle C, Chapuy-Regaud S, Pavili L, Prisant N, Izopet J, Bujan L, Mansuy JM. *Kinetics of anti-ZIKV antibodies after Zika infection using two commercial enzyme-linked immunoassays*. **Diagn Microbiol Infect Dis** 2018;90:26-30.

40. Pasquier C, Saune K, Raymond S, Boineau J, Courtade M, Izopet J. *Comparison of Cobas(R) HPV and Anyplex II HPV28 assays for detecting and genotyping human papillomavirus*. **Diagn Microbiol Infect Dis** 2017;87:25-27.

41. Pasquier C, Walschaerts M, Raymond S, Moinard N, Saune K, Daudin M, Izopet J, Bujan L. *Patterns of residual HIV-1 RNA shedding in the seminal plasma of patients on effective antiretroviral therapy*. **Basic Clin Androl** 2017;27:17.

42. Prost S, Crossan CL, Dalton HR, De Man RA, Kamar N, Selves J, Dhaliwal C, Scobie L, Bellamy COC. *Detection of viral hepatitis E in clinical liver biopsies*. **Histopathology** 2017;71:580-590.

43. Puissant-Lubrano B, Puissochet S, Congy-Jolivet N, Chauveau D, Decramer S, Garnier A, Huart A, Kamar N, Ribes D, Blancher A. *Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab*. **Clin Immunol** 2017;183:1-7.

44. Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C and Dat ASG. *Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen*. **J Antimicrob Chemother** 2017;72:3502.

45. Raymond S, Nicot F, Jeanne N, Delfour O, Carcenac R, Lefebvre C, Cazabat M, Saune K, Delobel P, Izopet J. *Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use.* **Sci Rep** 2017;7:42215.
46. Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J and Group AARS. *Impact of HIV-1 minority variants on the virus response to a rilpivirine-based first line regimen.* **Clin Infect Dis** (sous presse). (IF 8,2)
47. Rizkallah J, Kamar N, Bello AD. *Acute antibody mediated rejection following sleeve gastrectomy in a kidney-transplant recipient treated with a belatacept-Mycophenolate mofetil based therapy.* **Surg Obes Relat Dis** 2017;13:e19-e20.
48. Saliba F, Duvoux C, Gugenheim J, Kamar N, Dharancy S, Salame E, Neau-Cransac M, Durand F, Houssel-Debry P, Vanlemmens C, Pageaux G, Hardwigsen J, Eyraud D, Calmus Y, Di Giambattista F, Dumortier J, Conti F. *Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial.* **Am J Transplant** 2017;17:1843-1852.
49. Sayed IM, Foquet L, Verhoye L, Abravanel F, Farhoudi A, Leroux-Roels G, Izopet J, Meuleman P. *Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma.* **Antiviral Res** 2017;141:150-154.
50. Sayed IM, Verhoye L, Cocquerel L, Abravanel F, Foquet L, Montpellier C, Debing Y, Farhoudi A, Wychowski C, Dubuisson J, Leroux-Roels G, Neyts J, Izopet J, Michiels T, Meuleman P. *Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.* **Gut** 2017;66:920-929.
51. Serrero M, Planes R, Bahraoui E. *PKC-delta isoform plays a crucial role in Tat-TLR4 signalling pathway to activate NF-kappaB and CXCL8 production.* **Sci Rep** 2017;7:2384.
52. Soulie C, Grude M, Descamps D, Amiel C, Morand-Joubert L, Raymond S, Pallier C, Bellecave P, Reigadas S, Trabaud MA, Delaugerre C, Montes B, Barin F, Ferre V, Jeulin H, Alloui C, Yerly S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haim-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG and Group AARS. *Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.* **J Antimicrob Chemother** 2017;72:2351-2354.
53. Srivastava R, Khan AA, Chilukuri S, Syed SA, Tran TT, Furness J, Bahraoui E, BenMohamed L. *CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8(+) TEM and CD8(+) TRM Cells within Infected Tissues Allows Efficient Protection against Recurrent Herpesvirus Infection and Disease.* **J Virol** 2017;91.
54. van Eijk JJJ, Dalton HR, Ripellino P, Madden RG, Jones C, Fritz M, Gobbi C, Melli G, Pasi E, Herrod J, Lissmann RF, Ashraf HH, Abdelrahim M, Masri O, Fraga M, Benninger D, Kuntzer T, Aubert V, Sahli R, Moradpour D, Blasco-Perrin H, Attarian S, Gerolami R, Colson P, Giordani MT, Hartl J, Pischke S, Lin NX, McLean BN, Bendall RP, Panning M,

Peron JM, Kamar N, Izopet J, Jacobs BC, van Alfen N, van Engelen BGM. *Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy*. **Neurology** 2017;89:909-917.

55. Velay A, Kack-Kack W, Abravanel F, Lhomme S, Leyendecker P, Kremer L, Chamouard P, Izopet J, Fafi-Kremer S, Barth H. *Parsonage-Turner syndrome due to autochthonous acute genotype 3f hepatitis E virus infection in a nonimmunocompromised 55-year-old patient*. **J Neurovirol** 2017;23:615-620.

56. Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, de Man RA, van der Laan LJW, Huang F, Kamar N, Peppelenbosch MP, Pan Q. *RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production*. **Hepatology** 2017;65:1823-1839.

57. Yin X, Li X, Ambardekar C, Hu Z, Lhomme S, Feng Z. *Hepatitis E virus persists in the presence of a type III interferon response*. **PLoS Pathog** 2017;13:e1006417.

58. Zhou X, Huang F, Xu L, Lin Z, de Vrij FMS, Ayo-Martin AC, van der Kroeg M, Zhao M, Yin Y, Wang W, Cao W, Wang Y, Kushner SA, Marie Peron J, Alric L, de Man RA, Jacobs BC, van Eijk JJ, Aronica EMA, Sprengers D, Metselaar HJ, de Zeeuw CI, Dalton HR, Kamar N, Peppelenbosch MP, Pan Q. *Hepatitis E Virus Infects Neurons and Brains*. **J Infect Dis** 2017;215:1197-1206.

Equipe 7 Pathogénèse des infections virales du système nerveux central adulte et en développement (D. Dunia / C. Casper)

1. Denadai-Souza A, Ribeiro CM, Rolland C, Thouard A, Deraison C, Scavone C, Gonzalez-Dunia D, Vergnolle N, Avellar MCW. *Effect of tryptase inhibition on joint inflammation: a pharmacological and lentivirus-mediated gene transfer study*. **Arthritis Res Ther**. 2017 Jun 6;19(1):124. doi: 10.1186/s13075-017-1326-9.

2. Omarsdottir S, Agnarsdottir M, Casper C, Orrego A, Vanpée M, Rahbar A, Söderberg-Nauclér C. *High prevalence of cytomegalovirus infection in surgical intestinal specimens from infants with necrotizing enterocolitis and spontaneous intestinal perforation: A retrospective observational study*. **J Clin Virol**. 2017 Aug;93:57-64.

3. Dicky O, Ehlinger V, Montjoux N, Gremmo-Féger G, Sizun J, Rozé JC, Arnaud C, Casper C; EPIPAGE 2 Nutrition Study Group; EPINUTRI Study Group. *Policy of feeding very preterm infants with their mother's own fresh expressed milk was associated with a reduced risk of bronchopulmonary dysplasia*. **Acta Paediatr**. 2017 May;106(5):755-762.

4. Casper C, Kuhn P. *The care of extremely preterm infants: A French view of the Swedish experience*. **Arch Pediatr**. 2017 Nov;24(11):1123-1128.

5. Bar C, Diene G, Molinas C, Bieth E, Casper C, Tauber M. *Early diagnosis and care is achieved but should be improved in Orphanet* **J Rare Dis**. 2017 Jun 28;12(1):118

6. Cortey A, Renesme L, Raignoux J, Bedu A, Casper C, Tourneux P, Truffert P. *Management of jaundice in the newborn ≥ 35 GW: From screening to follow-up after discharge*. Guidelines for clinical practice. **Arch Pediatr**. 2017 Feb;24(2):192-203.

7. Dicky O, Ehlinger V, Guyard-Boileau B, Assouline C, Arnaud C, Casper C. *Delayed umbilical cord clamping in preterm infants born before 37 weeks of gestation: A prospective observational study*. Arch Pediatr. **2017** Feb;24(2):118-125.

Equipe 8 Parasites eucaryotes intracellulaires : immunité et chimiorésistance (N. Blanchard)

1. Lebrun M, Blanchard N. *Editorial overview: Host-microbe interactions: parasites*. **Curr Opin Microbiol**. 2017 Dec;40:viii-xi. doi: 10.1016/j.mib.2017.11.028. No abstract available.

2. Santi-Rocca J, Blanchard N. *Membrane trafficking and remodeling at the host-parasite interface*. **Curr Opin Microbiol**. 2017 Dec;40:145-151. doi: 10.1016/j.mib.2017.11.013. Epub 2017 Nov 22. Review.

3. Draheim M, Wlodarczyk MF, Crozat K, Saliou JM, Alayi TD, Tomavo S, Hassan A, Salvioni A, Demarta-Gatsi C, Sidney J, Sette A, Dalod M, Berry A, Silvie O, Blanchard N. *Profiling MHC II immunopeptidome of blood-stage malaria reveals that cDC1 control the functionality of parasite-specific CD4 T cells*. **EMBO Mol Med**. 2017 Nov;9(11):1605-1621. doi: 10.15252/emmm.201708123.

4. Bonnard C, Feuillet G, Vasseur V, Cenac N, Vergnolle N, Blanchard N. *Protease-activated receptor 2 contributes to Toxoplasma gondii-mediated gut inflammation*. **Parasite Immunol**. 2017 Nov;39(11). doi: 10.1111/pim.12489. Epub 2017 Sep 27.

5. Keita Alassane S, Nicolau-Travers ML, Menard S, Andreoletti O, Cambus JP, Gaudre N, Wlodarczyk M, Blanchard N, Berry A, Abbes S, Colongo D, Faye B, Augereau JM, Lacroux C, Iriart X, Benoit-Vical F. *Young Sprague Dawley rats infected by Plasmodium berghei: A relevant experimental model to study cerebral malaria*. **PLoS One**. 2017 Jul 24;12(7):e0181300. doi: 10.1371/journal.pone.0181300. eCollection 2017.

6. Buaille C, Guerrero NA, Cebrian I, Blanié S, Lopez J, Bassot E, Vasseur V, Santi-Rocca J, Blanchard N. *MHC I presentation of Toxoplasma gondii immunodominant antigen does not require Sec22b and is regulated by antigen orientation at the vacuole membrane*. **Eur J Immunol**. 2017 Jul;47(7):1160-1170. doi: 10.1002/eji.201646859. Epub 2017 Jun 8.

7. Pagès A, Iriart X, Molinier L, Georges B, Berry A, Massip P, Juillard-Condât B. *Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit*. **Value Health**. 2017 Dec;20(10):1319-1328. doi: 10.1016/j.jval.2017.06.009. Epub 2017 Aug 7.

8. Guery R, Henry B, Martin-Blondel G, Rouzaud C, Cordoliani F, Harms G, Gangneux JP, Foulet F, Bourrat E, Baccard M, Morizot G, Consigny PH, Berry A, Blum J, Lortholary O, Buffet P; French Cutaneous Leishmaniasis Study group & the LeishMan network. *Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea*. **PLoS Negl Trop Dis**. 2017 Nov 20;11(11):e0006094. doi: 10.1371/journal.pntd.0006094. eCollection 2017 Nov.

9. Sandeu MM, Bayibéki AN, Tchioffo MT, Abate L, Gimonneau G, Awono-Ambéné PH, Nsango SE, Diallo D, Berry A, Texier G, Morlais I. *Do the venous blood samples*

replicate malaria parasite densities found in capillary blood? A field study performed in naturally-infected asymptomatic children in Cameroon. **Malar J.** 2017 Aug 17;16(1):345. doi: 10.1186/s12936-017-1978-6.

10.Noël H, Ruello M, Maccary A, Pelat C, Sommen C, Boissier J, Barré-Cardi H, Fillaux J, Termignon JL, Debruyne M, Chyderiotis G, Durand J, Ramalli L, Chiappini JD, Malfait P, Berry A. *Large outbreak of urogenital schistosomiasis acquired in Southern Corsica, France: monitoring early signs of endemicization?* **Clin Microbiol Infect.** 2017 Jun 30. pii: S1198-743X(17)30350-6. doi: 10.1016/j.cmi.2017.06.026.

11.Magnaval JF, Laurent G, Gaudré N, Fillaux J, Berry A. *A diagnostic protocol designed for determining allergic causes in patients with blood eosinophilia.* **Mil Med Res.** 2017 May 23;4:15. doi: 10.1186/s40779-017-0124-7. eCollection 2017.

12.Kincaid-Smith J, Rey O, Toulza E, Berry A, Boissier J. *Emerging Schistosomiasis in Europe: A Need to Quantify the Risks.* **Trends Parasitol.** 2017 Aug;33(8):600-609. doi: 10.1016/j.pt.2017.04.009. Epub 2017 May 21. Review.

13.Berry A, Iriart X, Fillaux J, Magnaval JF. [*Urinary schistosomiasis and cancer*]. **Bull Soc Pathol Exot.** 2017 Feb;110(1):68-75. doi: 10.1007/s13149-017-0547-4. Epub 2017 Feb 10. Review.

14.Armengol C, Cassaing S, Roques-Malecaze C, Chauvin P, Iriart X, Berry A, Fillaux J. *Time before anti-Toxoplasma IgG seroconversion detection by 7 commercial assays in French pregnant women.* **Diagn Microbiol Infect Dis.** 2017 Feb;87(2):103-107. doi: 10.1016/j.diagmicrobio.2016.10.020. Epub 2016 Oct 22.

Equipe 9 Mécanismes moléculaires de la croissance, de l'ostéogenèse et de l'ostéolyse ; biothérapies (JP Salles)

1.Fruchon S, Poupot R. *Pro-Inflammatory Versus Anti-Inflammatory Effects of Dendrimers: The Two Faces of Immuno-Modulatory Nanoparticles.* **Nanomaterials (Basel).** 2017 Sep 1;7(9). pii: E251. doi: 10.3390/nano7090251. Review.

2.Tauber M, Boulanouar K, Diene G, Çabal-Berthoumieu S, Ehlinger V, Fichaux-Bourin P, Molinas C, Faye S, Valette M, Pourrinet J, Cessans C, Viaux-Sauvelon S, Bascoul C, Guedeney A, Delhanty P, Geenen V, Martens H, Muscatelli F, Cohen D, Consoli A, Payoux P, Arnaud C, Salles JP. *The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader-Willi Syndrome.* **Pediatrics.** 2017 Feb;139(2). pii: e20162976. doi: 10.1542/peds.2016-2976.

3.Rothenbuhler A, Esterle L, Gueorguieva I, Salles JP, Mignot B, Colle M, Linglart A. *Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR).* **Growth Horm IGF Res.** 2017 Oct;36:11-15. doi: 10.1016/j.ghir.2017.08.001. Epub 2017 Aug 15.

4.Estrade S, Majorel C, Tahhan N, Dulac Y, Baunin C, Gennero I, Chaix Y, Salles JP, Edouard T. [*Severe nutritional rickets in young children: Resurgence of an old disease*].

Arch Pediatr. 2017 Aug;24(8):737-742. doi: 10.1016/j.arcped.2017.05.004. Epub 2017 Jun 28. French. **If 0.372**

5. Burnett LC, LeDuc CA, Sulsona CR, Paull D, Rausch R, Eddiry S, Carli JF, Morabito MV, Skowronski AA, Hubner G, Zimmer M, Wang L, Day R, Levy B, Fennoy I, Dubern B, Poitou C, Clement K, Butler MG, Rosenbaum M, Salles JP, Tauber M, Driscoll DJ, Egli D, Leibel RL. *Deficiency in prohormone convertase PCI impairs prohormone processing in Prader-Willi syndrome.* **J Clin Invest.** 2017 Jan 3;127(1):293-305. doi: 10.1172/JCI88648. Epub 2016 Dec 12.

6. Viaux-Savelon S, Rosenblum O, Guedeney A, Diene G, Çabal-Berthoumieu S, Fichaux-Bourin P, Molinas C, Faye S, Valette M, Bascoul C, Cohen D, Tauber M. *Dyssynchrony and perinatal psychopathology impact of child disease on parents-child interactions, the paradigm of Prader Willi syndrom.* **J Physiol Paris.** 2016 Nov;110(4 Pt B):427-433. doi: 10.1016/j.jphysparis.2017.08.001. Epub 2017 Sep 1. Review.

7. Bar C, Diene G, Molinas C, Bieth E, Casper C, Tauber M. *Early diagnosis and care is achieved but should be improved in infants with Prader-Willi syndrome.* **Orphanet J Rare Dis.** 2017 Jun 28;12(1):118. doi: 10.1186/s13023-017-0673-6.

8. Henaux S, Ruysse-Witrand A, Cantagrel A, Barnetche T, Fautrel B, Filippi N, Lukas C, Raffener B, Rossini M, Degboé Y, Constantin A. *Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.* **Ann Rheum Dis.** 2017 Nov 29. pii: annrheumdis-2017-212423. doi: 10.1136/annrheumdis-2017-212423. [Epub ahead of print]

9. Laustriat G, Ruysse-Witrand A, Constantin A, Barnetche T, Adoue D, Cantagrel A, Degboé Y. *Anti-citrullinated peptides antibodies in systemic sclerosis: Meta-analysis of frequency and meaning.* **Joint Bone Spine.** 2017 Nov 26. pii: S1297-319X(17)30196-3. doi: 10.1016/j.jbspin.2017.11.006. [Epub ahead of print]

10. Ruysse-Witrand A, Jamard B, Cantagrel A, Nigon D, Loeuille D, Degboe Y, Constantin A. *Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort.* **RMD Open.** 2017 Sep 7;3(2):e000482. doi: 10.1136/rmdopen-2017-000482. eCollection 2017.

11. Pécourneau V, Degboé Y, Barnetche T, Cantagrel A, Constantin A, Ruysse-Witrand A. *Effectiveness of Exercise Programs in Ankylosing Spondylitis: A Meta-Analysis of Randomized Controlled Trials.* **Arch Phys Med Rehabil.** 2017 Aug 30. pii: S0003-9993(17)31019-5. doi: 10.1016/j.apmr.2017.07.015. [Epub ahead of print] Review.

12. Degboé Y, Fajadet B, Laurent C, Cantagrel A, Constantin A, Ruysse-Witrand A. *A rare case of rheumatoid pachyleptomeningitis successfully treated with rituximab.* **Rheumatology (Oxford).** 2017 Jul 1;56(7):1238-1240. doi: 10.1093/rheumatology/kex059. No abstract available.

13. Baradat C, Degboé Y, Constantin A, Cantagrel A, Ruysse-Witrand A. *No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-*

analysis. **RMD Open**. 2017 Feb 22;3(1):e000352. doi: 10.1136/rmdopen-2016-000352. eCollection 2017.

14.Mabille C, Witrand AR, Degboe Y, Gennero I, Loiseau HA, Roussel M, Hebraud B, Nigon D, Attal M, Laroche M. *DKK1 and sclerostin are early markers of relapse in multiple myeloma*. **Bone**. 2017 Oct 6. pii: S8756-3282(17)30370-8. doi: 10.1016/j.bone.2017.10.004. [Epub ahead of print]

Equipe 10 Bases moléculaires et déterminismes physiologiques de la signalisation dans les lymphocytes T (R. Lesourne)

1.Garreau A, Blaize G, Argenty J, Rouquié N, Tourdès A, Wood SA, Saoudi A, Lesourne R. *Grb2-Mediated Recruitment of USP9X to LAT Enhances Thymic Stability following Thymic Selection*. **J Immunol**. 2017 Oct 15;199(8):2758-2766. doi: 10.4049/jimmunol.1700566. Epub 2017 Sep 6.

2.Choi S, Cornall R, Lesourne R, Love PE. *THEMIS: Two Models, Different Thresholds*. **Trends Immunol**. 2017 Sep;38(9):622-632. doi: 10.1016/j.it.2017.06.006. Epub 2017 Jul 8. Review.

3.Duguet F, Locard-Paulet M, Marcellin M, Chaoui K, Bernard I, Andreoletti O, Lesourne R, Burret-Schiltz O, Gonzalez de Peredo A, Saoudi A. *Proteomic Analysis of Regulatory T Cells Reveals the Importance of Themis1 in the Control of Their Suppressive Function*. **Mol Cell Proteomics**. 2017 Aug;16(8):1416-1432. doi: 10.1074/mcp.M116.062745. Epub 2017 Apr 3.

4.Choi S, Warzecha C, Zvezdova E, Lee J, Argenty J, Lesourne R, Aravind L, Love PE. *THEMIS enhances TCR signaling and enables positive selection by selective inhibition of the phosphatase SHP-1*. **Nat Immunol**. 2017 Apr;18(4):433-441. doi: 10.1038/ni.3692. Epub 2017 Feb 27.

5.Cheng D, Deobagkar-Lele M, Zvezdova E, Choi S, Uehara S, Baup D, Bennett SC, Bull KR, Crockford TL, Ferry H, Warzecha C, Marcellin M, de Peredo AG, Lesourne R, Anzilotti C, Love PE, Cornall RJ. *Themis2 lowers the threshold for B cell activation during positive selection*. **Nat Immunol**. 2017 Feb;18(2):205-213. doi: 10.1038/ni.3642. Epub 2016 Dec

Equipe : Manuel Diaz-Munoz

1.Díaz-Muñoz MD, Kiselev VY, Le Novère N, Curk T, Ule J, Turner M. *Tial dependent regulation of mRNA subcellular location and translation controls p53 expression in B cells*. **Nat Commun**. 2017 Sep 13;8(1):530. doi: 10.1038/s41467-017-00454-2.